Compound information
- Natural Products
- ZC3655216
- Molecular Formula
- C20H20Cl2N2O3S
- Molecular Weight
- 438.05716886 g/mol
- Structure
-
- IUPAC Name
- (1R,3S)-3-(2,2-dichlorovinyl)-N-[4-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)thiazol-2-yl]-2,2-dimethyl-cyclopropanecarboxamide
- InChI
- InChI=1S/C20H20Cl2N2O3S/c1-20(2)12(9-16(21)22)17(20)18(25)24-19-23-13(10-28-19)11-4-5-14-15(8-11)27-7-3-6-26-14/h4-5,8-10,12,17H,3,6-7H2,1-2H3,(H,23,24,25)/t12-,17+/m1/s1
- InChI Key
- AFFZQAHLBRYCLT-PXAZEXFGSA-N
- SMILES
- CC1(C)[C@H](C=C(Cl)Cl)[C@H]1C(=O)Nc1nc(-c2ccc3c(c2)OCCCO3)cs1
- Source
- ZINC000041004285
Warheads
- Cyclopropane
-
ADMET Property
Physicochemical Property
| Property | Value | Property | Value |
|---|---|---|---|
| Heavy Atom Count | 28 | Ring Count | 4 |
| Heteroatom Count | 8 | Rotatable Bond Count | 4 |
| Hydrogen Bond Acceptor Count | 5 | Hydrogen Bond Donor Count | 1 |
| Topological Polar Surface Area | 60.45 Å2 | LogP | 5.602 |
| LogS | -7.162 | LogD | 4.952 |
Absorption
| Property | Value | Property | Value |
|---|---|---|---|
| Pgp inhibitor | 0.192 | Pgp substrate | 0.001 |
| HIA | 0.966 | F20 % | 0.985 |
| F30 % | 0.903 | Caco-2 | -4.499 |
| MDCK | -4.734 |
Distribution
| Property | Value | Property | Value |
|---|---|---|---|
| BBB Penetration | 0.01 | PPB | 98.325 |
| VD | 1.826 | Fu | 1.341 |
Metabolism
| Property | Value | Property | Value |
|---|---|---|---|
| CYP1A2 inhibitor | 1.0 | CYP1A2 substrate | 0.606 |
| CYP2A6 substrate | 0.719 | CYP2B6 substrate | 0.8 |
| CYP2C19 inhibitor | 0.965 | CYP2C19 substrate | 0.926 |
| CYP2C8 substrate | 0.694 | CYP2C9 inhibitor | 0.989 |
| CYP2C9 substrate | 1.0 | CYP2D6 inhibitor | 0.024 |
| CYP2D6 substrate | 0.783 | CYP2E1 substrate | 0.538 |
| CYP3A4 inhibitor | 0.956 | CYP3A4 substrate | 1.0 |
Excretion
| Property | Value | Property | Value |
|---|---|---|---|
| T1/2 | 0.08 | CL | 8.781 |
Toxicity
| Property | Value | Property | Value |
|---|---|---|---|
| hERG Blockers | 0.152 | Hepatotoxicity | 0.551 |
| Mutagenicity | 0.176 | Rat Oral Acute Toxicity | 0.464 |
| FDAMDD | 0.209 | Skin Sensitization | 0.001 |
| Carcinogenicity | 0.027 | Eye Corrosion | 0.003 |
| Eye Irritation | 0.013 | Respiratory Toxicity | 0.978 |
Environmental Toxicity
| Property | Value | Property | Value |
|---|---|---|---|
| Bioconcentration Factors | 0.912 | IGC50 | 4.224 |
| LC50FM | 6.807 | LC50DM | 6.531 |
Tox21 Pathway
| Property | Value | Property | Value |
|---|---|---|---|
| NR-AR | 0.673 | NR-AR-LBD | 0.375 |
| NR-AhR | 0.871 | NR-Aromatase | 0.79 |
| NR-ER | 0.743 | NR-ER-LBD | 0.726 |
| NR-PPAR-gamma | 0.866 | SR-ARE | 0.81 |
| SR-ATAD5 | 0.652 | SR-HSE | 0.547 |
| SR-MMP | 0.915 | SR-p53 | 0.773 |
Similar covalent drugs
No similar covalent drugs found for this compound.